158 related articles for article (PubMed ID: 31200352)
1. Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor-Positive Breast Cancer.
Roberts MC; Kurian AW; Petkov VI
J Natl Compr Canc Netw; 2019 Jun; 17(6):662-668. PubMed ID: 31200352
[TBL] [Abstract][Full Text] [Related]
2. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
3. Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.
Hull LE; Lynch JA; Berse BB; DuVall SL; Chun DS; Venne VL; Efimova OV; Icardi MS; Kelley MJ
Clin Breast Cancer; 2018 Apr; 18(2):135-143. PubMed ID: 29306660
[TBL] [Abstract][Full Text] [Related]
4. Association of Social Determinants and Tumor Biology With Racial Disparity in Survival From Early-Stage, Hormone-Dependent Breast Cancer.
Hoskins KF; Calip GS; Huang HC; Ibraheem A; Danciu OC; Rauscher GH
JAMA Oncol; 2023 Apr; 9(4):536-545. PubMed ID: 36795405
[TBL] [Abstract][Full Text] [Related]
5. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
[TBL] [Abstract][Full Text] [Related]
6. Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources.
Akinyemiju T; Moore JX; Ojesina AI; Waterbor JW; Altekruse SF
Breast Cancer Res Treat; 2016 Jun; 157(3):575-86. PubMed ID: 27255533
[TBL] [Abstract][Full Text] [Related]
7. Disparities in Breast Cancer Survival by Socioeconomic Status Despite Medicare and Medicaid Insurance.
Silber JH; Rosenbaum PR; Ross RN; Reiter JG; Niknam BA; Hill AS; Bongiorno DM; Shah SA; Hochman LL; Even-Shoshan O; Fox KR
Milbank Q; 2018 Dec; 96(4):706-754. PubMed ID: 30537364
[TBL] [Abstract][Full Text] [Related]
8. HER2 status and disparities in luminal breast cancers.
Holowatyj AN; Ruterbusch JJ; Ratnam M; Gorski DH; Cote ML
Cancer Med; 2016 Aug; 5(8):2109-16. PubMed ID: 27250116
[TBL] [Abstract][Full Text] [Related]
9. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
[TBL] [Abstract][Full Text] [Related]
10. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
Sparano JA; Wang M; Zhao F; Stearns V; Martino S; Ligibel JA; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE
J Natl Cancer Inst; 2012 Mar; 104(5):406-14. PubMed ID: 22250182
[TBL] [Abstract][Full Text] [Related]
11. Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
Holowatyj AN; Cote ML; Ruterbusch JJ; Ghanem K; Schwartz AG; Vigneau FD; Gorski DH; Purrington KS
J Clin Oncol; 2018 Mar; 36(7):652-658. PubMed ID: 29341832
[TBL] [Abstract][Full Text] [Related]
12. The impact of socioeconomic status and race on trial participation for older women with breast cancer.
Gross CP; Filardo G; Mayne ST; Krumholz HM
Cancer; 2005 Feb; 103(3):483-91. PubMed ID: 15597407
[TBL] [Abstract][Full Text] [Related]
13. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women.
Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Fair AM; Sanderson M; Shu XO; Kelley MC; Zheng W
Clin Breast Cancer; 2014 Dec; 14(6):417-25. PubMed ID: 24970715
[TBL] [Abstract][Full Text] [Related]
14. Underutilization of gene expression profiling for early-stage breast cancer in California.
Cress RD; Chen YS; Morris CR; Chew H; Kizer KW
Cancer Causes Control; 2016 Jun; 27(6):721-7. PubMed ID: 27097910
[TBL] [Abstract][Full Text] [Related]
15. Influence of provider factors and race on uptake of breast cancer gene expression profiling.
Reeder-Hayes KE; Wheeler SB; Baggett CD; Zhou X; Meng K; Roberts MC; Carey LA; Meyer AM
Cancer; 2018 Apr; 124(8):1743-1751. PubMed ID: 29338090
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Roberts MC; Miller DP; Shak S; Petkov VI
Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
[TBL] [Abstract][Full Text] [Related]
17. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.
Chen L; Li CI
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1666-72. PubMed ID: 26464428
[TBL] [Abstract][Full Text] [Related]
18. Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers.
Purrington KS; Gorski D; Simon MS; Hastert TA; Kim S; Rosati R; Schwartz AG; Ratnam M
Breast Cancer Res Treat; 2020 May; 181(1):145-154. PubMed ID: 32236827
[TBL] [Abstract][Full Text] [Related]
19. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
[TBL] [Abstract][Full Text] [Related]
20. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care.
Freedman RA; Virgo KS; He Y; Pavluck AL; Winer EP; Ward EM; Keating NL
Cancer; 2011 Jan; 117(1):180-9. PubMed ID: 20939011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
